Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 4/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 13/20 | 0.42 |
| ▸ | KLK1 | P06870 | 8/20 | 0.42 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144228 | 0.78 | MAPT (0.48) | ROCK1KLKB1MAPTCYP1A2CYP2A6 | |
| SCHEMBL16881300 | 0.77 | KLKB1 (0.70) | KLKB1KLK1MAP4K1 | |
| SCHEMBL17909748 | 0.74 | KLKB1 (0.48) | KLKB1MAP4K1 | |
| SCHEMBL17442590 | 0.72 | KLKB1 (0.43) | KLKB1MAP4K1 | |
| SCHEMBL14908371 | 0.71 | ROCK1 (0.47) | ROCK1KLKB1MAPTCYP1A2CYP2A6 | |
| SCHEMBL16881369 | 0.70 | KLKB1 (0.43) | KLKB1MAP4K1 | |
| SCHEMBL805508 | 0.68 | CYP1A2 (0.53) | MAPTCYP1A2CYP2A6 | |
| SCHEMBL3065915 | 0.68 | CYP2A6 (0.57) | ROCK1MAPTCYP1A2CYP2A6 | |
| SCHEMBL21363718 | 0.68 | CYP19A1 (0.41) | ROCK1KLKB1KLK1MAPTCYP1A2 | |
| SCHEMBL17253659 | 0.68 | ABL1 (0.49) | CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | COR THERAPEUTICS, INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036296-A1 | BENZAMIDES AND RELATED INHIBITORS OF FACTOR XA | TFPI, F12, TFPI2 | ROCK1 3758/4885KLKB1 192/4885KLK1 637/4885 |
| US-10179124-B2 | Benzamides and related inhibitors of factor Xa | TFPI, F12, TFPI2 | ROCK1 3758/4885KLKB1 192/4885KLK1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.